MedTrace Logo

Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer

NCT02331134 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-05-31

Study results available
· View outcomes & findings →

Summary

The overall goal of this study is to develop a pre-clinical platform of melanoma and head and neck squamous cell cancer that will allow the investigators to learn more about these diseases and discover better and more individualized treatments.

Conditions

Interventions

DRUG

Filgrastim

Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule

Sponsors & Collaborators

  • Karsh Family Research Fund

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Antonio Jimeno, MD, PhD · University of Colorado, Denver

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-13
Primary Completion
2018-07-06
Completion
2025-03-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02331134 on ClinicalTrials.gov